ClinicalTrials.gg
CompletedNCT05102409Updated Feb 28, 2025Results posted

An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap and Lifitegrast in a Dry Eye Disease Chamber

A Phase 2 interventional study of Reproxalap Ophthalmic Solution (0.25%) and Xiidra® (5% lifitegrast ophthalmic solution) in Dry Eye, sponsored by Aldeyra Therapeutics, Inc.. Completed at 1 site in Canada. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-02-28.

Sponsored by Aldeyra Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
56
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing reproxalap in Dry Eye Syndromes — none open to participants now, none under way, none of them phase 3. reproxalap · Dry Eye Syndromes.

Enrollment
10th of 11
56 · median 158
Started
2021
with 3 others
Phase 2
5 of 11
none open now
Registered
7th of 11
by date
Lead sponsor
11 of 11
Aldeyra Therapeutics, Inc.

Among the 11 studies testing reproxalap in Dry Eye Syndromes, this one is the 10th largest by enrollment, is one of 4 that started in 2021, is one of 5 in phase 2, and was the 7th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

None of the 11 studies testing reproxalap in Dry Eye Syndromes is open now. The open studies under Dry Eye Syndromes, anywhere →

Where they have run

About reproxalap

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing reproxalap in Dry Eye Syndromes as a file.
02

Study summary

An Exploratory, Single-Center, Double-Masked, Crossover Clinical Trial to Assess Safety and Tolerability of 0.25% Reproxalap Ophthalmic Solution Compared to Xiidra® in Subjects with Dry Eye Disease in a Dry Eye Chamber

03

Conditions studied

  • Dry Eye

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Eighteen (18) to70 years of age at the time of screening (either gender and any race).
  2. Ability to provide written .
  3. Reported history of dry eye for at least 6 months prior to Visit 1.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of an ongoing ocular infection (bacterial, viral, or fungal) or active ocular inflammation at Visit 1.
  2. Contact lens use within 7 days of Visit 1 or anticipate using contact lenses during the trial.
  3. A condition that the investigator feels may put the subject at significant risk may confound the study results or may interfere significantly with the subject's participation in the trial.
  4. Inability or unwillingness to follow instructions, including participation in all study assessments/procedures and visits.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Reproxalap Ophthalmic Solution (0.25%)

    Single dose

    Drug: Reproxalap Ophthalmic Solution (0.25%)

  • Active comparator
    Xiidra® (5% lifitegrast ophthalmic solution)

    Single dose

    Drug: Xiidra® (5% lifitegrast ophthalmic solution)

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Ocular Discomfort

    Ocular discomfort (0 = none, 10 = extremely severe) was reported by patients in a dry eye chamber. Change from baseline was analyzed using a mixed model repeated measures (MMRM) analysis, with baseline as a covariate, and treatment and intra-chamber time point as factors.

    Time frame: The efficacy assessment period was approximately every 5 minutes during a 45-minute dry eye chamber. Baseline was prior to dosing for each treatment period.

  2. Change From Baseline in Ocular Itching

    Ocular itching (0 = none, 10 = extremely severe) was reported by patients in a dry eye chamber. Change from baseline was analyzed using a MMRM analysis, with baseline as a covariate, and treatment and intra-chamber time point as factors.

    Time frame: The efficacy assessment period was approximately every 5 minutes during a 45-minute dry eye chamber. Baseline was prior to dosing for each treatment period.

07

Results

Posted Feb 28, 2025

Participant flow

Participant flow — Overall Study
MilestoneLifitegrast, Reproxalap
Started56
Completed54
Not completed2

Outcome measures

PrimaryChange From Baseline in Ocular Discomfort

Ocular discomfort (0 = none, 10 = extremely severe) was reported by patients in a dry eye chamber. Change from baseline was analyzed using a mixed model repeated measures (MMRM) analysis, with baseline as a covariate, and treatment and intra-chamber time point as factors.

Time frame:
The efficacy assessment period was approximately every 5 minutes during a 45-minute dry eye chamber. Baseline was prior to dosing for each treatment period.
Reported as:
Least squares mean · score on a scale
Change From Baseline in Ocular Discomfort
score on a scaleReproxalapLifitegrast
Change From Baseline in Ocular Discomfort1.35 ± 0.212.07 ± 0.25
PrimaryChange From Baseline in Ocular Itching

Ocular itching (0 = none, 10 = extremely severe) was reported by patients in a dry eye chamber. Change from baseline was analyzed using a MMRM analysis, with baseline as a covariate, and treatment and intra-chamber time point as factors.

Time frame:
The efficacy assessment period was approximately every 5 minutes during a 45-minute dry eye chamber. Baseline was prior to dosing for each treatment period.
Reported as:
Least squares mean · score on a scale
Change From Baseline in Ocular Itching
score on a scaleReproxalapLifitegrast
Change From Baseline in Ocular Itching0.93 ± 0.211.54 ± 0.25

Adverse events

Collected over One day for each intervention. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Reproxalap0/54 (0%)0/54 (0%)40/54 (74.1%)
Lifitegrast0/56 (0%)0/56 (0%)12/56 (21.4%)
Most frequent other events
Most frequent other events
EventReproxalapLifitegrast
General DisordersGeneral disorders40/546/56
Nervous System DisordersNervous system disorders0/546/56

Baseline characteristics

Enrolled subjects

Age, Continuous
Age, Continuous(years)Lifitegrast, Reproxalap
Mean47.9 ± 12.4
Sex: Female, Male
Sex: Female, Male(Participants)Lifitegrast, Reproxalap
Female36
Male20
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lifitegrast, Reproxalap
Hispanic or Latino9
Not Hispanic or Latino47
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Lifitegrast, Reproxalap
American Indian or Alaska Native0
Asian12
Native Hawaiian or Other Pacific Islander0
Black or African American6
White33
More than one race5
Unknown or Not Reported0
08

Study locations

1 site
  • Cliantha Research
    Mississauga, Ontario, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Oct 2021, 1 month.

Results were first posted in Feb 2025, 3 years 4 months after primary completion. A results delay was requested in Sep 2022.

Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's 1 month is below that.

Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2021
First posted
Nov 1, 2021
StartActual
Sep 9, 2021
Primary completionActual
Oct 25, 2021
CompletionActual
Oct 25, 2021
Results delay requested
Sep 26, 2022
Results first posted
Feb 28, 2025
Last update
Feb 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05102409
Responsible party
Sponsor
First posted
Nov 1, 2021
Start date
Sep 9, 2021
Primary completion
Oct 25, 2021
Completion
Oct 25, 2021
Results posted
Feb 28, 2025
Last update
Feb 28, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Reproxalap

Start the discussion